Orthox Revenue and Competitors

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox's exceptionally strong, resilient, regenerative hydrogel technology, FibroFixâ„¢ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFixâ„¢ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFixâ„¢ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFixâ„¢, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strengthâ„¢.